Thermo Fisher Scientific (NYSE: TMO) reported earnings today. Here are the numbers you need to know.

The 10-second takeaway
For the quarter ended March 31 (Q1), Thermo Fisher Scientific beat expectations on revenues and beat expectations on earnings per share.

Compared to the prior-year quarter, revenue grew and GAAP earnings per share expanded significantly.

Gross margins increased, operating margins shrank, and net margins dropped.

Revenue details
Thermo Fisher Scientific tallied revenue of $3.10 billion. The 17 analysts polled by S&P Capital IQ predicted net sales of $2.98 billion on the same basis. GAAP reported sales were 14% higher than the prior-year quarter's $2.72 billion.

Source: S&P Capital IQ. Quarterly periods. Dollar amounts in millions. Non-GAAP figures may vary to maintain comparability with estimates.

EPS details
Non-GAAP EPS came in at $1.17. The 19 earnings estimates compiled by S&P Capital IQ forecast $1.11 per share on the same basis. GAAP EPS of $0.75 for Q1 were 17% higher than the prior-year quarter's $0.64 per share.

Source: S&P Capital IQ. Quarterly periods. Non-GAAP figures may vary to maintain comparability with estimates.

Margin details
For the quarter, gross margin was 43.4%, 210 basis points better than the prior-year quarter. Operating margin was 11.9%, 70 basis points worse than the prior-year quarter. Net margin was 8.9%, 40 basis points worse than the prior-year quarter.

Looking ahead
Next quarter's average estimate for revenue is $3.07 billion. On the bottom line, the average EPS estimate is $1.16.

Next year's average estimate for revenue is $12.32 billion. The average EPS estimate is $4.77.

Investor sentiment
The stock has a five-star rating (out of five) at Motley Fool CAPS, with 539 members rating the stock outperform and 23 members rating it underperform. Among 169 CAPS All-Star picks (recommendations by the highest-ranked CAPS members), 166 give Thermo Fisher Scientific a green thumbs-up, and three give it a red thumbs-down.

Of Wall Street recommendations tracked by S&P Capital IQ, the average opinion on Thermo Fisher Scientific is outperform, with an average price target of $62.89.